Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

NCT06305702 · clinicaltrials.gov ↗

COMPLETED

Status

500

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Metastatic Breast Cancer

Interventions

DRUG: inetetamab

Sponsor

Liaoning Cancer Hospital & Institute